Preventing CMV with letermovir after stem cell transplant
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are scheduled to have a stem cell transplant from a donor who is a good match.
- You or your donor has had CMV in the past (CMV-positive blood test).
- You have no CMV in your blood right now (tested within 5 days before starting).
- You have good kidney and liver function, and your heart and lungs work well enough for the transplant.
- You have not taken certain antiviral drugs (like ganciclovir, valganciclovir) in the past week or certain others in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This study looks at two viruses (CMV and TTV) in adults who have had a stem cell transplant. It tests how a preventive antiviral medicine (letermovir) affects these viruses over time.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This trial tests a treatment using specially grown immune cells (virus-specific lymphocytes) to fight a stubborn CMV infection that hasn't gotten better with usual medicines. It is for people who have had a stem cell transplant and need help controlling CMV.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.